TRAIL-combinatietherapie wellicht
gunstig bij behandeling hersentumor GBM
Patiënten met een glioblastoma (GBM), een kwaadaardige hersentumor, hebben een slechte
prognose. Ondanks de standaardbehandeling van chirurgie, radiotherapie en chemotherapie is
de mediane overleving maar iets meer dan een jaar. Neurochirurg Jos Kuijlen van het UMCG
onderzocht de mogelijkheden om de behandeling te verbeteren op basis van de TNF Related
Apoptosis Inducing Ligand (TRAIL), een molecuul dat een binding aangaat met
TRAIL-receptoren op het celmembraan van GBM cellen, waarna celdood geïnduceerd kan
worden.
Verbazingwekkend dat de KWF geen
preventieve maatregelen doorgeeft; dat wat al JAAAAREN BEKEND IS ! Pas op in uw land, waar
IEDEREEN zich gewoon 'therapeut' kan noemen; dit is LEVENSGEVAARLIJK. De resultaten zijn
de zien in de 'zorg', een woord wat in Nederland niet meer gebruikt mag worden omdat
'zorg' geen zorg is. En na die slechte zorg, (ZE MAKEN U GEWOON KAPOT, gefinancierd door
de Overheid), kunt u een 'geautoriseerd spuitje' krijgen om uit uw lijden verlost te
worden.......'zorg'......geheten; maar WAAROM vertelt NIEMAND van 'regulier' HOE te
herstellen ??? Heeft u zich dat wel eens afgevraagd ?
Veel kunt u ZELF doen om te voorkomen dat u
in die criminele spiraal terchtkomt, in Nederland 'zorg' geheten.....jaja...
Zorg voor een doorstroming van 100% VAN KOP
TOT TEEN:
4x per jaar erkende osteopathie om uw
wervelkolom te laten controleren zodat ophopingen van uw eigen vuil verwijderd worden
(helaas vindt u dit niet in Nederland, maar wel erbuiten, dus oppassen )
elke dag 10 minuten voetreflexologie; de
voorkant van uw voet staat in verbinding met de bovenkant van uw hoofd
elke ochtend zout water snuiven om uw hoofd
schoon te houden
drink voldoende water om uw waterniveau van
kop tot teen vol en op peil te houden
beweeg voldoende, doe rek en strek
oefeningen
voorkom klappen op het hoofd
doe een helm op bij diverse activiteiten
acupunctuur - acupressuur, uiteraard alles
erkend, dus niet in Nederland te vinden
DvH
Risico op tweede tumor bepalen bij
hoofd-halskanker
Tieneke Schaaij-Visser heeft een aantal
eiwitten geidentificeerd waarmee in behandelde patienten voorspeld kan worden welke van
hen een groter risico lopen op een tweede tumor. Jaarlijks krijgen in Nederland 2500
mensen hoofd-halskanker, oftewel kanker die ontstaat in het slijmvlies van de mondholte,
de keel en het strottenhoofd. Hoofd-halskanker is hardnekkig, omdat bij 40% van de
patienten de kanker na chirurgische behandeling zal terugkomen. Tot dusver was het
onmogelijk om te voorspellen bij welke patienten dit wel of juist niet zou gebeuren. Voor
dit onderzoek vergeleek ze honderden eiwitten uit normale, premaligne en tumorweefsels uit
patienten. Hieruit bleek dat een aantal eiwitten sterk verschilden tussen normaal en
tumorweefsel. Vervolgens testte ze in verschillende patientengroepen of deze eiwitten
bruikbaar waren voor het voorspellen van de ontwikkeling van een tumor. De resultaten
toonden aan dat de vermindering van de eiwitten keratine 4 en cornuline significant
correleerde met het ontstaan van de tweede tumor in geopereerde patienten. Patienten met
een mogelijk verhoogd risico op het terugkomen van de kanker komen in aanmerking voor
extra controle in het ziekenhuis en eventueel preventieve behandeling. Aanvullend
onderzoek is nodig om nieuw beleid te maken ten aanzien van extra ziekenhuiscontroles voor
risicopatienten. Onderzoek naar preventieve behandelingen is al gaande en zal ook verder
ontwikkeld moeten worden.
Revolutionary Brain Cancer
Treatment With Avastin
Doctors have completed the sixth successful
procedure of a revolutionary brain cancer treatment, which forgoes traditional methods and
delivers the chemo drug Avastin directly into the tumor. Dr. John Boockvar discusses the
procedure with CNBC
'U' Researchers: 'Batman' the Dog
Still Cancer Free
Researchers at the University of Minnesota
say there's positive news for 'Batman'—a 10-year-old German shepherd battling a rare
tumor. The school used an experimental combination of gene therapy and a vaccine to an
aggressive brain tumor from Batman in 2008. Wednesday marked his one-year check up and
doctors say he's still cancer free. "The life expectancy for this dog was probably
less than two months if he had gone untreated," explained Professor John Ohlfest.
Researchers say the study could have far-reaching implications in treating brain cancer in
humans.
Cell Phones give Brain Cancer
Combined radiation seed,
chemotherapy wafer implants show promise in treating cancerous brain tumors
In the battle against malignant brain tumors, dual implantation of radioactive seeds and
chemotherapy wafers following surgery showed promising results in a study led by
specialists at the Neuroscience Institute at the University of Cincinnati and University
Hospital.
UC Davis researchers find molecule
that targets brain tumors
UC Davis Cancer Center researchers report today the discovery of a molecule that targets
glioblastoma, a highly deadly form of cancer. The finding, which is published in the
January 2009 issue of the European Journal of Nuclear Medicine and Molecular Imaging,
provides hope for effectively treating an incurable cancer. Glioblastoma is the most
common and aggressive type of primary brain tumor in adults. It is marked by tumors with
irregular shapes and poorly defined borders that rapidly invade neighboring tissues,
making them difficult to remove surgically. "These brain tumors are currently treated
with surgery to remove as much of the tumor as possible followed by radiation to kill
cancer cells left behind and systemic chemotherapy to prevent spread to nearby
tissues," said Kit Lam, senior author of the study and UC Davis chief of hematology
and oncology. "It is unfortunate that this approach does not extend survival
significantly. Most patients survive less than one year."
Brain cancer study - Magnitude of
post-vaccine immune response linked to clinical outcomes
Researchers conducting a clinical trial of a dendritic cell vaccine designed to fight
malignant brain tumors called glioblastoma multiforme have found a correlation between the
"intensity" of a patient's immune response and clinical outcome, according to an
article in the July 15 issue of the journal Cancer Research.
Protein in Common Virus Linked to
Aggressive Brain Tumors
A protein found in the common human virus cytomegalovirus (CMV) appears to be a key factor
in making brain tumors more aggressive and faster spreading. That’s the finding of a
new study in the journal Cancer Research. The researchers, from the California Pacific
Medical Center Research Institute, say the protein known as IE1 plays a number of roles,
modifying brain cancer cells in a way that makes them grow more rapidly, and confirming a
potential role for CMV in the malignant process of this cancer. “IE1 delivers a
one-two punch to tumor cells. We detect the CMV IE1 protein in nearly all malignant brain
tumors, and we find that it can make tumor cells more aggressive by affecting two major
pathways,” says Charles Cobbs, M.D, the lead author of the study. “First, it
inhibits two key tumor suppressor proteins in the brain tumor cells; then it promotes the
most important growth signaling pathway in the tumor itself. By modulating these cellular
pathways, this viral protein makes the tumor cells more aggressive.”
Three-drug combination
"extremely promising" as first-line therapy for multiple myeloma, researchers
say
A new combination of bortezomib (Velcade) and two other drugs is showing a very high
response rate in patients newly diagnosed with multiple myeloma, a team headed by
Dana-Farber Cancer Institute investigators reported at the annual meeting of the American
Society of Hematology.
Research Suggests New Treatment
Suitable for All Patients With Least-Curable Brain Tumors
New research at Wake Forest University Baptist Medical Center suggests that a three-drug
cocktail may one day improve outcomes in patients with glioblastoma multiforme (GBM), a
type of brain tumor with a dismal prognosis. Two of the drug candidates have been
developed, and the team is working on the third – all targeted to kill or impair
cancer cells and spare healthy brain.
Mayo Clinic identifies best
treatments for long-term survival in brain tumor patients
A new Mayo Clinic study found that patients with low-grade gliomas survived longest when
they underwent aggressive surgeries to successfully remove the entire tumor. If safely
removing the entire tumor was not possible, patients survived significantly longer when
surgery was followed by radiation therapy. This study is available online as an advance
publication in Neuro-Oncology
(http://neuro-oncology.dukejournals.org/cgi/content/abstract/15228517-2008-102v1). Gliomas
are a type of brain tumor that form in the brain or spinal cord tissue and can spread
within the nervous system. Low-grade gliomas are malignant and slow growing; overall,
patients' average survival is five to seven years after diagnosis, even with treatment.
Annually, about 17,000 Americans are diagnosed with a glioma. Of that total, 3,000 to
4,000 are categorized as low-grade. Mayo Clinic physicians treat more than 4,000 adults
and children who have gliomas and other brain and nervous system tumors each year.
"Mayo Clinic has a long history of expertise in treating patients with brain
tumors," says Nadia Laack, M.D., a Mayo Clinic radiation oncologist and lead author
of this study. "This makes our study unique in terms of the large volumes of patients
seen here and the extensive length of follow-up." Dr. Laack and a team of Mayo Clinic
researchers studied the records of 314 adult patients with low-grade gliomas who were
diagnosed between 1960 and 1992 and had an average of 13 years of follow-up. Nearly half
of the patients who underwent aggressive surgeries (gross total resection or radical
subtotal resection) were free of tumor recurrence 15 years after diagnosis.
Childhood brain tumor traced to
normal stem cells gone bad
An aggressive childhood brain tumor known as medulloblastoma originates in normal brain
"stem" cells that turn malignant when acted on by a known mutant, cancer-causing
oncogene, say researchers from Dana-Farber Cancer Institute and the University of
California, San Francisco. The findings hint at potential new treatment approaches for
medulloblastoma by targeting the origins of the tumors, and further suggest that not all
patients' tumors may be born from the same cells.
Medulloblastoma is one of the most common and most malignant brain tumours among children
and teenagers. These tumours grow very rapidly, and fifty percent of patients in the long
term die from the condition. The details of the processes that lead to the growth of these
tumours have remained unknown until now. In two studies, working together with
international scientific teams, LMU medical scientist Dr. Ulrich Schüller has now
successfully revealed certain molecular mechanisms that lead to the development of these
cerebellar tumours. As reported in the current issue of the journal “Cancer
Cell”, the researchers triggered genetic changes in cell populations in the brains of
mice in order to provoke the growth of tumours. It turned out that medulloblastomas arose
from only one type of cell – granule cells – and only if these were already
fully committed. “Medulloblastomas are presently treated with nonspecific
methods,” states Schüller. “Our results could contribute to the development of
targeted therapies, and thus improve the treatment of cerebellar tumours in
children.”
